{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T03:44:51Z","timestamp":1766807091737},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T00:00:00Z","timestamp":1489363200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"UCB Pharma (Brussels, Belgium)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s40262-017-0530-8","type":"journal-article","created":{"date-parts":[[2017,3,13]],"date-time":"2017-03-13T09:32:08Z","timestamp":1489397528000},"page":"1403-1413","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy"],"prefix":"10.1007","volume":"56","author":[{"given":"Andreas","family":"Lindauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Laveille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armel","family":"Stockis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,13]]},"reference":[{"key":"530_CR1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","volume":"110","author":"MA Rogawski","year":"2015","unstructured":"Rogawski MA, Tofighy A, White HS, et al. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015;110:189\u2013205.","journal-title":"Epilepsy Res"},{"key":"530_CR2","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","volume":"48","author":"E Ben-Menachem","year":"2007","unstructured":"Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48:1308\u201317.","journal-title":"Epilepsia"},{"key":"530_CR3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","volume":"50","author":"P Hal\u00e1sz","year":"2009","unstructured":"Hal\u00e1sz P, K\u00e4lvi\u00e4inen R, Mazurkiewicz-Beldzi\u0144ska M, et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50:443\u201353.","journal-title":"Epilepsia"},{"key":"530_CR4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","volume":"51","author":"S Chung","year":"2010","unstructured":"Chung S, Sperling MR, Biton V, et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia. 2010;51:958\u201367.","journal-title":"Epilepsia"},{"key":"530_CR5","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/epi.12681","volume":"55","author":"RT Wechsler","year":"2014","unstructured":"Wechsler RT, Li G, French J, et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: results from a historical-controlled, multicenter, double-blind study. Epilepsia. 2014;55:1088\u201398.","journal-title":"Epilepsia"},{"key":"530_CR6","unstructured":"Committee for Medicinal Products for Human Use. Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders: CHMP\/EWP\/566\/98 Rev.2\/Corr. London: European Medicines Agency; 2010."},{"key":"530_CR7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1474-4422(16)30292-7","volume":"16","author":"M Baulac","year":"2017","unstructured":"Baulac M, Rosenow F, Toledo M, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol. 2017;16:43\u201354.","journal-title":"Lancet Neurol"},{"key":"530_CR8","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1528-1167.2006.00585.x","volume":"47","author":"T Glauser","year":"2006","unstructured":"Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094\u2013120.","journal-title":"Epilepsia"},{"key":"530_CR9","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","volume":"68","author":"MJ Brodie","year":"2007","unstructured":"Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68:402\u20138.","journal-title":"Neurology"},{"key":"530_CR10","unstructured":"Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ, editors. NONMEM users guides (1989\u20132011). Ellicott City (MD): Icon Development Solutions; 2011. http:\/\/www.iconplc.com\/innovation\/nonmem\/ . Accessed 7 March 2017."},{"key":"530_CR11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241\u201357.","journal-title":"Comput Methods Programs Biomed"},{"key":"530_CR12","unstructured":"R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2007. http:\/\/www.R-project.org\/ . Accessed 7 March 2017."},{"key":"530_CR13","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/FTD.0b013e31815c15f3","volume":"29","author":"K Vuci\u0107evi\u0107","year":"2007","unstructured":"Vuci\u0107evi\u0107 K, Miljkovi\u0107 B, Velickovi\u0107 R, et al. Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data. Ther Drug Monit. 2007;29:781\u20138.","journal-title":"Ther Drug Monit"},{"key":"530_CR14","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/bcp.12121","volume":"76","author":"AK Frobel","year":"2013","unstructured":"Frobel AK, Karlsson MO, Backman JT, et al. A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A. Br J Clin Pharmacol. 2013;76:603\u201315.","journal-title":"Br J Clin Pharmacol"},{"key":"530_CR15","unstructured":"Abrantes J, Almeida A, Sales F, et al. A repeated time-to-event model for epileptic seizures in patients undergoing antiepileptic drug withdrawal during video-EEG monitoring [abstract]. In: 23rd annual meeting of the population approach group in Europe, June 10\u201313, Alicante, Spain. 2014. p. 3180. http:\/\/www.page-meeting.org\/?abstract=3180\/ . Accessed 7 March 2017."},{"key":"530_CR16","unstructured":"Karlsson MO, Holford N. A tutorial on visual predictive checks [abstract]. In: 17th annual meeting of the population approach group in Europe. June 18\u201320, Marseille, France. 2008. p. 1434. http:\/\/www.page-meeting.org\/?abstract=1434\/ . Accessed 7 March 2017."},{"key":"530_CR17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011555016423","volume":"28","author":"Y Yano","year":"2001","unstructured":"Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic\/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28:171\u201392.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"530_CR18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1684\/epd.2012.0513","volume":"14","author":"MJ Brodie","year":"2012","unstructured":"Brodie MJ. Novel trial designs for monotherapy. Epileptic Disord. 2012;14:132\u20137.","journal-title":"Epileptic Disord"},{"key":"530_CR19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1684\/epd.2012.0511","volume":"14","author":"E Perucca","year":"2012","unstructured":"Perucca E. What clinical trial designs have been used to test antiepileptic drugs and do we need to change them? Epileptic Disord. 2012;14:124\u201331.","journal-title":"Epileptic Disord"},{"key":"530_CR20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/clpt.1989.108","volume":"46","author":"LB Sheiner","year":"1989","unstructured":"Sheiner LB, Beal SL, Sambol NC. Study designs for dose-ranging. Clin Pharmacol Ther. 1989;46:63\u201377.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-017-0530-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0530-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-017-0530-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T23:12:27Z","timestamp":1719097947000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-017-0530-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,13]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["530"],"URL":"https:\/\/doi.org\/10.1007\/s40262-017-0530-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,13]]}}}